Healthineers Draws Matching 49-Euro Targets From Goldman and LBBW Despite Softer 2027 Guide

Siemens Healthineers picked up two identical price targets on the same day, yet the stock still slipped — a reminder that upgraded valuations and upgraded fundamentals are not the same thing.

Goldman Sachs lifted its target to 49 euros from 43 while keeping a "Neutral" rating, and LBBW reportedly moved to the same 49-euro mark from 42, albeit with a Buy recommendation attached. The two houses now converge on the price but part ways on conviction. Shares in the medical-technology group fell 2.6% as the more guarded outlook for fiscal 2027 weighed on sentiment.

A Cluster of Higher Targets

The Goldman and LBBW moves cap a busy stretch of revisions. Analysts had already raised their targets on Friday and the day before, with new marks spanning 51.00 to 55 euros; all of those carried positive ratings that were left untouched. Barclays, according to media reports, lifted its target to 51 euros from 47.50 euros on Friday while reaffirming "Overweight."

Not everyone moved. UBS kept "Neutral" and a 38-euro target on Thursday, and two further assessments published the same day also stood pat — both reaffirmed their positive views, with targets between 48 and 50 euros. The shares closed at 44.70 euros on Friday, down 0.1%.

The 2027 Number That Sits Below 2026

At the heart of the caution is a profit guide that lands under last year's mark. For fiscal 2027, Siemens Healthineers projects adjusted earnings per share of 2.20 to 2.40 euros, against 2.42 euros booked in fiscal 2026. Comparable revenue growth is guided at 4.0% to 5.0% — a range Reuters reported as falling short of analyst expectations.

Management pinned the softer planning on persistent weakness in China. Finance chief Jochen Schmitz said, according to Dow Jones, that the guidance bakes in more conservative China assumptions, including a slight revenue decline in both Imaging and Precision Therapy in that market.

A Solid Close to Fiscal 2026

The Thursday release for the fourth quarter of fiscal 2026 offered a firmer counterpoint. Comparable revenue growth came in at 5.9%, the adjusted EBIT margin reached 15.9%, and adjusted earnings per share were 0.69 euros.

Alongside the numbers, the company has been steadily shrinking its share count. Between 26 October and 1 November inclusive, it bought back 50,000 shares, a purchase disclosed on 2 November. Since the programme began on 1 June, roughly 3.6 million shares had been repurchased through 1 November, based on trades settled by that date.

Investors get the full picture on 25 November 2026, when Siemens Healthineers is scheduled to publish its annual report for fiscal 2026.